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http://www.lipidworld.com/content/13/1/43RESEARCH Open AccessThe effects of obesity, diabetes and metabolic
syndrome on the hydrolytic enzymes of the
endocannabinoid system in animal and human
adipocytes
Jemma C Cable1, Garry D Tan2, Stephen PH Alexander3 and Saoirse E O'Sullivan1*Abstract
Background: Circulating endocannabinoid levels are increased in obesity and diabetes. We have shown that fatty
acid amide hydrolase (FAAH, an endocannabinoid hydrolysing enzyme) in subcutaneous adipose tissue positively
correlates with BMI in healthy volunteers. The aim of the present study was to investigate whether the hydrolytic
enzymes of the endocannabinoid system are affected by diabetes or metabolic syndrome in obesity.
Methods: Using radiolabelled substrates, FAAH and monoacylglycerol lipase (MGL) activities were assessed in
adipocytes from various adipose depots in Zucker rats (n = 22, subcutaneous abdominal, visceral and epididymal)
and bariatric patients (n = 28, subcutaneous abdominal and omental).
Results: FAAH activity was significantly increased in adipocytes of obese (Zucker Fatty) compared to Zucker lean
rats (P < 0.05) but was not raised in the Zucker Diabetic Fatty rats (ZDF). MGL activity was raised in both Zucker
Fatty (P < 0.001-0.01) and ZDF rats (P < 0.05) and was positively correlated with body weight and plasma glucose
levels (P < 0.01). In bariatric patients (BMI range 37–58 kg.m2), there was a trend for MGL activity to correlate
positively with BMI, reaching significance when type 2 diabetic patients were removed. FAAH and MGL activities in
obese humans were not correlated with blood pressure, skinfold thicknesses, fasting glucose, insulin, HbA1c,
triglycerides or cholesterol levels.
Conclusions: FAAH in adipocytes is differentially altered in animal models of obesity and diabetes, while MGL
activity is increased by both. However, in obese humans, FAAH or MGL activity in adipocytes is not affected by
diabetes, dyslipidaemia or other markers of metabolic dysfunction. This suggests increased circulating levels of
endocannabinoids are not a result of altered degradation in adipose tissue.
Keywords: Endocannabinoid, Adipose, Adipocyte, Obesity, Type 2 diabetes, Fatty acid amide hydrolase (FAAH),
Monoacylglycerol lipase (MGL), Rat, HumanIntroduction
The endocannabinoid system (ECS) is crucial in the regula-
tion of metabolism and energy homeostasis (see [1-4]). The
ECS is comprised of endocannabinoid ligands, their recep-
tors, and the enzymes required for their synthesis and deg-
radation. N-arachidonoylethanolamide (anandamide, AEA)* Correspondence: mbzso@nottingham.ac.uk
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unless otherwise stated.[5] and 2-arachidonoylglycerol (2-AG) [6,7] are the two
best characterised endocannabinoids, and the enzymes
which degrade them are predominantly fatty acid amide
hydrolase (FAAH) and monoacylglycerol lipase (MGL) re-
spectively [8,9]. Other N-acylethanolamines such as oleoy-
lethanolamide (OEA) and palmitoylethanolamide (PEA)
are also degraded by FAAH.
It has been suggested that the ECS is upregulated in
human obesity on the basis that plasma concentrations
of AEA [10,11], 2-AG [12] and other acyl-ethanolamides
[13] correlate positively with body mass index (BMI).td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Cable et al. Lipids in Health and Disease 2014, 13:43 Page 2 of 11
http://www.lipidworld.com/content/13/1/43We have shown that FAAH activity in mature subcutane-
ous adipocytes correlates positively with BMI in healthy
volunteers [14]. However, BMI is a crude measure of adi-
posity and the adverse metabolic consequences of obesity
are more closely related to centripetal obesity. It is there-
fore relevant that circulating 2-AG levels [10] and FAAH
activity in subcutaneous adipocytes [14] also correlate
with waist circumference, and the most significant rise in
plasma 2-AG occurs in those with visceral obesity [11,12].
The peripheral ECS may be dysregulated in type 2 dia-
betes, as first suggested in a study showing increased con-
centrations of AEA and 2-AG in plasma in patients with
type 2 diabetes compared to BMI-matched controls [15]. In
subcutaneous adipose tissue, AEA is increased and 2-AG is
decreased in obese humans with type 2 diabetes compared
to lean and obese non-diabetic controls [16]. Hyperinsuli-
naemia (using a clamp) also causes an upregulation of
FAAH mRNA in subcutaneous abdominal adipose tissue of
lean subjects, but no change in the obese group, in which
FAAH was already chronically upregulated [17]. However,
any influence of hyperinsulinaemia or other metabolic fac-
tors on functional FAAH or MGL enzyme activity (as op-
posed to mRNA levels) have not been assessed.
Visceral adipose tissue is more metabolically active than
subcutaneous adipose tissue [18], but there is conflicting evi-
dence as to whether the ECS differs significantly between
these depots. In subjects with a BMI less than 25 kg.m2, can-
nabinoid 1 (CB1) receptor mRNA expression is higher
[19,20], unchanged [21] or lower [11] in subcutaneous com-
pared to visceral adipose tissue. In obese subjects, CB1 recep-
tor mRNA expression is elevated [11,19,21] or not different
[20] in visceral compared to subcutaneous adipose tissue.
FAAH mRNA expression is increased [11] or unchanged
[21] in visceral compared to subcutaneous adipose tissue. A
higher expression of MGL mRNA in subcutaneous com-
pared to visceral adipose [21] is consistent with increased
levels of 2-AG reported in visceral adipose tissue [15]. How-
ever, the catalytic activities of FAAH and MGL have not
been compared between different adipose tissue depots.
In light of this background, the primary aim of the
current study was to investigate if obesity co-morbidities
and metabolic risk factors, including hyperinsulinaemia,
hyperglycaemia and dyslipidaemia, influence FAAH and
MGL enzyme activities in adipose tissue. The secondary
aim was to determine whether FAAH or MGL activities
differ between visceral and subcutaneous adipocytes.
These objectives were first explored in rat models of
obesity and type 2 diabetes, and subsequently in severely
obese patients undergoing bariatric surgery.
Results
Enzyme activity
In the rat samples tested, as expected, FAAH activity was
present in the total particulate fraction of the homogenisedadipocytes, but was not detected in the cytosolic fraction,
while the majority of adipocyte MGL activity was detected
in the cytosolic fraction (Figure 1). Anandamide hydrolysis
was suppressed by the FAAH inhibitor URB597 (P <
0.0001) and 2-OG hydrolysis was suppressed by a non-
specific MGL inhibitor, methoxy arachidonyl fluoropho-
sphonate (MAFP, P < 0.0001, Figure 1). The % coefficient
variation of FAAH and MGL assays performed in dupli-
cate were 15.96 ± 15.13 (mean ± SD) and 12.88 ± 15.13
respectively.
The effects of obesity/diabetes on FAAH and MGL activity
in Zucker rats
Comparing FAAH activity in adipose depots from obese
diabetic rats with that from lean and obese Zuckers indi-
cated levels of activity more similar to those observed in
lean Zuckers than in obese (Figure 2A-C). In fact, FAAH
activities in adipocytes from obese diabetic rats were sig-
nificantly reduced compared to those from obese ani-
mals in epididymal adipocytes (P < 0.01, Figure 2C).
Within all rat strains, abdominal adipocyte FAAH activity
correlated positively with body mass (P < 0.05, Figure 3A).
There was no correlation between blood glucose levels
and FAAH activity (data not shown); however, when the
diabetic animals were removed from this analysis, a posi-
tive correlation was observed between FAAH activity and
blood glucose in the subcutaneous and abdominal adipo-
cytes (see Figure 3G,H).
In subcutaneous adipocytes, MGL activities for the obese
and obese diabetic rats were 18- and 12-fold increased com-
pared to the lean animals (P < 0.01 and P < 0.05, Figure 2D).
In abdominal adipocytes the corresponding values were 5-
and 3-fold, respectively (P < 0.001 and P < 0.05, Figure 2E),
and in epididymal adipocytes, MGL activity was 5- and 3.5-
fold increased (P < 0.001 and P < 0.05, Figure 2F). A positive
relationship was identified between MGL activity and body
mass in all adipose tissues (abdominal r = 0.67, P < 0.001;
subcutaneous r = 0.63, P < 0.01; epididymal r = 0.76, P <
0.0001, Figure 3D,E,F). MGL activity also correlated with
blood glucose levels in adipocytes from all three adipose tis-
sue depots (subcutaneous r = 0.53, P < 0.05; abdominal r =
0.56, P < 0.01; epididymal r = 0.48, P < 0.05), and this effect
became stronger when the diabetic rats were removed (See
Figure 3J,K,L).
The effects of adipose depots on FAAH and MGL activity
In the lean rats, there was no significant difference in FAAH
activity between adipose depots (see Figure 2A-C), but MGL
activity was found to be lower in the subcutaneous adipo-
cytes than either the abdominal and epididymal adipocytes
(P < 0.05, Figure 4A). In the obese and obese diabetic rats,
neither FAAH nor MGL activity in adipocytes differed
between the three adipose tissue depots tested (see


















































































































Figure 1 Endocannabinoid degradation enzyme assay validation. FAAH activity was detected in the total particulate and not cytosolic
fraction of adipocyte homogenates of Zucker rats (A, n = 48), and was significantly inhibited by URB597 (1 μM, C, n = 48). MGL activity was
detected in the cytosolic and not total particulate fraction of adipocyte homogenates (B, n = 33), and was significantly inhibited by MAFP (1 μM,























































































































































































Figure 2 Endocannabinoid degradation enzymes in lean and obese Zucker rats. FAAH and MGL activities in mature adipocytes isolated
from subcutaneous (A,D), abdominal (B,E) and epididymal (C,F) adipose tissue depots in lean (n = 6), obese (n = 8) and obese diabetic Zucker
rats (n = 8). Data are given as means, with error bars representing S.D., and were analysed by Krustal Wallis with comparisons between the means
of all data (* P < 0.05, ** P < 0.01, *** P < 0.001).
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r=0.46, P=0.0457 r=0.25, P=0.26 r=0.37, P=0.10
r=0.67, P=0.0011 r=0.63, P=0.0027 r=0.76, P<0.0001
r=0.7950, P=0.0018
r=0.795, P=0.0336 r=0.4334, P=0.1223
r=0.7943, P=0.0011 r=0.6777, P=0.0095 r=0.7195, P=0.0049
Figure 3 Correlation studies in Zucker rats. Correlative studies between body weight and enzyme activity in mature adipocytes isolated from
each adipose tissue depot in abdominal (A,D), subcutaneous (B,E), and epididymal (C,F) adipocytes. When the Zucker diabetic rats were omitted
from analysis, a significant correlation was observed between FAAH activity and plasma glucose levels in the abdominal (G) and subcutaneous
(H) but not epididymal adipocytes (I). Stronger correlations were also seen between MGL activity and plasma glucose levels in all adipose depots
(J,K,L). The Spearman correlation coefficient is reported. Key: green, lean rats; red, obese rats; black, obese diabetic rats.
Cable et al. Lipids in Health and Disease 2014, 13:43 Page 4 of 11
http://www.lipidworld.com/content/13/1/43(Figure 4B) and MGL (Figure 4C) activities did not differ be-
tween paired subcutaneous and visceral adipocytes. All sub-
sequent analysis was carried out in subcutaneous adipocytes.
FAAH and MGL activity in obese patients
The physiological characteristics of these severely obese
patients are given in Table 1, which shows the sampledivided into three groups: patients with clinically diag-
nosed T2M (n = 10), patients without T2M but with at
least three markers of metabolic syndrome (21, n = 12),
and patients without diabetes and with only one or two
markers of metabolic syndrome (‘healthy’, n = 6). Be-
tween these groups, age, BMI, fasting serum insulin con-





































































































Figure 4 Endocannabinoid degradation enzymes in different adipose depots. MGL activity in paired samples of adipose tissue from lean
Zucker rats (A). FAAH (B) and MGL (C) activities in paired samples of subcutaneous and visceral mature adipocytes from obese humans (n = 14).
Data are presented as scatterplots and were analysed using Krustal Wallis with comparisons between the means of all data (A) or by Wilcoxon
matched-pairs signed rank test (B and C, *P < 0.05).
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and HbA1c were higher in the diabetic group than both
the healthy and metabolic syndrome groups (P < 0.05).
Patients in all groups were prescribed similar medica-
tions for dyslipidaemia and hypertension, but 5 patients
in the diabetic group were taking hypoglycaemic medica-
tion compared to none in the healthy and metabolic syn-
drome groups.
Within this sample of obese patients, neither FAAH ac-
tivity nor MGL activity in subcutaneous adipocytes corre-
lated with BMI or waist circumference, although there
was a trend for a positive correlation between MGL activ-
ity and BMI (P = 0.0975, r = 0.3195, Figure 5A). Removing
patients with diabetes revealed a significant correlation be-
tween MGL and BMI (P = 0.0408, r = 0.4861, Figure 5B).
FAAH and MGL activity were not correlated with various
skinfold measurements (abdominal, tricep, bicep, arm,
iliac crest, subscapular, and axilla). There was a trend for aTable 1 Characteristics of the patients included in this study
‘Healthy’ (n = 6)
Gender split (male: female) 0:6
Age (years) 44.0 ± 4.7
BMI (kg.m-2) 44.0 ± 4.7
Insulin (mU.L-1) 12.2 ± 3.1
Glucose (mmol.L-1) 5.0 ± 0.2~
HbA1c (%) 5.8 ± 0.1†
HOMA2-%S 85.8 ± 26.2
MAP (mmHg) 96.1 ± 4.8
Dyslipidaemia medication 1 (statin)
Hyperglycaemia medication 0
Hypertension medication 3 (1: ACE inhibitor; 2: ACE
inhibitor + thiazide diuretic)
3 (1: ACE
Values are given as mean ± S.E.M. ~*†#Values marked with the same characters are s
and Bonferroni post hoc test.negative correlation between FAAH activity and neck cir-
cumference (P = 0.061, r = −0.3586, Figure 5C). In the fe-
male only population, a positive correlation was seen
between MGL activity and abdominal skin fold thick-
ness (P = 0.0406, r = 0.43, Figure 5D).
FAAH and MGL activity were not different between
‘healthy’ patients and those with metabolic syndrome or
diagnosed T2M (Figure 6G,H). FAAH and MGL activity
did not correlate with blood pressure, heart rate or age
(data not shown), and were not different in patients with
a normal compared to high fasting glucose, or HbA1c
and were not correlated with plasma insulin levels
(Figure 6). FAAH or MGL activity in subcutaneous ad-
ipocytes was also not different between high and normal
risk groups with regard to triglycerides, total cholesterol
or HDL-cholesterol (see Figure 7). There was also no cor-
relation between FAAH or MGL activity with non-HDL-C
(data not shown).Metabolic syndrome (n = 12) Diagnosed T2D (n = 10)
3:8 2:8
44.5 ± 3.3 45.5 ± 2.7
46.3 ± 1.7 44.8 ± 1.5
14.0 ± 2.3 15.9 ± 1.9
5.1 ± 0.2* 8.7 ± 1.4~*
5.8 ± 0.3# 7.9 ± 0.7†#
71.4 ± 14.2 50.4 ± 6.8
96.3 ± 4.3 104.8 ± 3.6
1 (statin) 2 (statin)
0 5 (metformin)
inhibitor; 1: ACE inhibitor + β1 antagonist;
1: ACE inhibitor + thiazide diuretic)
3 (2: ACE inhibitor;
1: thiazide diuretic)
ignificantly different from each other (P < 0.05). Data analysed using ANOVA
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Figure 5 Endocannabinoid degradation enzymes in obese humans. The relationship between FAAH and MGL activity and BMI in the whole
population (A) and in the non-diabetic patients (B), and between FAAH and MGL activity and neck circumference (C) and abdominal skinfold
thickness in the female only population (D).
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The primary aim of this study was to determine whether
the activities of FAAH and MGL, two key catabolic en-
zymes of the ECS, are differentially affected by diabetes
or other markers of the metabolic syndrome in obesity.
FAAH was raised in obese rats, but not obese diabetic
rats, while MGL activity was elevated in both strains.
FAAH and MGL activities positively correlated with
body weight and blood glucose in the Zucker rats, but
MGL activity correlated more strongly. By contrast, in
severely obese humans, FAAH and MGL activity in adi-
pose tissue was not correlated with adiposity and were
not different between ‘healthy’, type 2 diabetic, metabolic
syndrome patients, or in patients with clinical elevated
blood glucose, poor glycaemic control or hyperlipid-
aemia. FAAH and/or MGL activities were not different
between visceral and subcutaneous adipose tissue de-
pots, except in the lean rats, where MGL activity was
higher in visceral compared to subcutaneous adipocytes.
The effects of obesity/diabetes on FAAH and MGL activity
in Zucker rats
We found that FAAH and MGL enzyme activities in ma-
ture adipocytes are increased in Zucker rats compared
to lean rats, and were positively correlated with body
mass in the rat strains MGL activity was also correlated
with blood glucose levels, and this relationship was
stronger when the diabetic rats were removed from ana-
lysis. A relationship between FAAH and blood glucosewas also observed without the diabetic rats. Given that
MGL has distinct roles in lipolysis and signalling, the in-
creased activity of MGL in our studies may reflect an in-
crease in the endocannabinoid signalling role of MGL
rather than lipolysis, since lipolytic enzymes are gener-
ally repressed in obesity. MGL activity was raised in both
the obese and obese diabetic rats suggesting a differen-
tial regulation of FAAH and MGL in diabetes in obesity.
The physiological consequence of this differential effect
of diabetes in obesity on enzyme activity is not clear. In
obese diabetic humans, AEA, but not 2-AG, is increased
in subcutaneous adipose tissue [16]. An increase in AEA
causing activation of CB1 could lead to unfavourable
metabolic effects, however an increase in PEA and OEA,
which are also degraded by FAAH [16], may be benefi-
cial. For example, OEA decreases food intake and lowers
hyperlipidaemia in obese rats via PPARα activation [22]
and both OEA and PEA can stimulate insulin and GLP-
1 secretion via activation of GPR119 [23,24].
The effects of metabolic markers on FAAH and MGL
activity in obese patients
Although we have shown in a healthy volunteer popula-
tion that FAAH enzyme activity in mature subcutaneous
adipocytes correlates with BMI (ranging from 19.1-
33.8 kg.m-2, 13), in the current population of severely
obese patients (BMIs 36.6 to 58.2 kg.m-2), there was no
further correlation between FAAH activity and BMI,
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Figure 6 Endocannabinoid degradation enzymes in metabolic syndrome and diabetes. The effects of fasting serum glucose concentration
(A,D), HbA1c (B,E) and insulin concentration (C,F) on FAAH and MGL activities in subcutaneous adipocytes from obese humans. Data are
presented as scatterplots, with error bars representing S.D., and were analysed using Student’s t test or linear regression. FAAH (G) and MGL
(H) activities in subcutaneous adipocytes from obese humans assigned to one of three groups based on the following criteria: healthy <2
components of metabolic syndrome (n= 6, triangles); metabolic syndrome ≥3 components of metabolic syndrome (n= 11, squares); diagnosed type 2
diabetes with or without metabolic syndrome (n= 10, circles). Data are presented as scatterplots, with error bars representing S.D., and were analysed
using one way ANOVA and Bonferroni post hoc test.
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http://www.lipidworld.com/content/13/1/43thicknesses. Interestingly, a 5% reduction in total body
weight following calorie restriction does not affect FAAH
mRNA [10] and a 10% weight loss in obese volunteers re-
sulted in a decrease in FAAH mRNA in gluteal, but not
abdominal, adipose tissue to levels lower than the lean
controls [25]. A possible conclusion from these findings is
that there is limit to the enzymatic capacity of FAAH
which no longer increases in proportion to BMI in our se-
verely obese patients.
In contrast to the data with FAAH activity, and in ac-
cordance to the animal data, we found a trend for a
positive correlation in the human bariatric patients be-
tween MGL and BMI (becoming significant without dia-
betic patients) and between MGL and adiposity in the
female only population. This confirms the differentialregulation of FAAH and MGL activity in adipocytes.
Since FAAH is regulated by both insulin and leptin, we
hypothesise that factors such as insulin and leptin resist-
ance in obesity oppose any further increases in FAAH
activity and that MGL must be under other regulating
factors.
In obese patients, there was no difference in FAAH or
MGL between patients with or without a diagnosis of
type 2 diabetes, or those with clinically elevated plasma
glucose, HbA1c or HOMA. Furthermore, no correlation
was observed between serum insulin levels and FAAH
or MGL activity. Together this suggests that within a se-
verely obese population, these metabolic variables do
not appear to influence FAAH or MGL activity. Similarly,
elevated blood pressure, neck circumference, triglycerides,
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Figure 7 Endocannabinoid degradation enzymes and blood lipids. The effects of fasting serum triglyceride concentration (A,D), total
cholesterol concentration (C,F), and HDL cholesterol concentration (B,E) on FAAH and MGL activities in subcutaneous adipocytes from obese
humans. Data are presented as scatterplots, with error bars representing S.D., and were analysed using Student’s t test.
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FAAH or MGL activity. However, it should be noted that
our patients achieved reasonably good glycaemic control
(HbA1c 7.9 ± 0.7), and were not hyperinsulinaemic.
Therefore, the finding that FAAH activity was reduced
in the ZDF rat and not diabetic humans might be as-
cribed to the fact that diabetes is uncontrolled in the
ZDF, and this idea should be further pursued. Interest-
ingly, another team reported that FAAH mRNA in
subcutaneous adipose tissue correlated positively with
blood glucose and insulin in men, but not in females
[11], which may be important given that the majority
of the patients in the current study were female. In-
deed, we observed a significantly lower level of FAAH
in our obese males. Any gender differences in the
regulation of FAAH might explain why our predomin-
antly female population did not show any significant
relationship between FAAH activity and variables such
as insulin sensitivity.
FAAH and MGL activities in different adipose depots
Visceral adipose tissue is thought to have greater meta-
bolic activity and a greater impact on cardiovascular
health [18]. Differences between adipose depots have
been reported for various components of the ECS. In
obese humans, CB1 receptor mRNA is higher in visceral
adipose tissue than subcutaneous [19,21]. FAAH mRNA
levels are the same between subcutaneous and visceral
adipose tissue in obese humans [1], or higher in visceralthan subcutaneous/gluteal adipose tissue in lean and
obese humans [11]. MGL is reported to be downregu-
lated in visceral adipose tissue [21,25]. No studies have
been published on the activities of FAAH or MGL en-
zymes in adipocytes from different adipose tissue depots.
In the present study, we found that FAAH and MGL ac-
tivities were not different in paired subcutaneous and
visceral adipocytes from obese patients. Similarly, no
differences were observed between the rat strains in
enzyme activity between adipose depots tested. This
suggests that the rate of endocannabinoid degradation
does not differ between visceral and subcutaneous ma-
ture adipocytes and it may be that differences in the
expression of the ECS in the stromal-vascular fraction
may account for the overall differences in mRNA ob-
served in other studies between depots, or that enzyme
mRNA does not reflect enzyme activities.
Conclusion
In summary, several previous studies have shown that in
obese humans, circulating endocannabinoid levels and
components of the ECS in adipose tissue are altered by
insulin or diabetes. The results presented in this study
show that FAAH and MGL enzyme activities are in-
creased in adipocytes from animal model of diabetes/
obesity. However, in subcutaneous mature adipocytes
from severely obese humans, FAAH and MGL enzyme
activities are not altered in relation to BMI, waist cir-
cumference, adipose tissue distribution, blood pressure,
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daemia. Differences between the animal and human
studies may be explained by gender, or differences in in-
sulin (and potentially other hormones) sensitivity. No
differences in the activity of FAAH or MGL were identi-
fied between subcutaneous and visceral adipocytes.
Methods
This study was approved by Derbyshire Regional Ethics
Committee (08/H0401/94) and Royal Derby Hospital
Trust (DHRD/2008/081), and recruited patients under-
going elective laparoscopic bariatric or cholecystectomy
surgery at Royal Derby Hospital. Informed written con-
sent was obtained in accordance with Good Clinical
Practice and the Declaration of Helsinki. The animals
were used in accordance with the Home Office Code of
Practice for the Housing and Care of Animals used in
Scientific Procedures and were killed by an appropriate
humane Schedule 1 method (cervical dislocation).
Animal models
Three strains of male Zucker rat were used; the lean
Zucker control (289 ± 6 g, 6.6 ± 0.3 mmol.L-1 glucose,
n = 6), Zucker Fatty (obese, 363 ± 7 g, 10.2 ± 0.6 mmol.
L-1, n = 8) and Zucker Diabetic Fatty (ZDF, obese dia-
betic, 325 ± 7 g, 18.3 ± 1.0 mmol.L-1, n = 8). After sacri-
fice, adipose tissue was immediately dissected from the
subcutaneous abdominal (inguinal), visceral (perirenal)
and epididymal adipose depots and immediately stored
at −80°C. Blood glucose concentration was measured
using a glucometer (Optium Xceed, Abbott Laboratories
Ltd., UK).
Clinical studies
Patients (23 women and 5 men, this split is representative
of the fact that more women were undergoing bariatric sur-
gery at the time) were recruited into one of three groups;
those diagnosed with T2M (diabetic, n = 10); patients with-
out diabetes, but with at least three markers of metabolic
syndrome (metabolic syndrome, n = 12) [26]; and those
without diabetes and with fewer than two markers of meta-
bolic syndrome (‘healthy’, n = 6). Markers of metabolic
syndrome included waist circumference ≥94 cm (male)
or ≥80 cm (female); serum triglyceride ≥1.7 mmol.L-1;
serum HDL-cholesterol <1 mmol.L-1 (male) or <1.3 mmol.L-1
(female); systolic blood pressure ≥130 mm Hg and/or dia-
stolic blood pressure ≥85 mm Hg; and fasting serum glu-
cose ≥5.6 mmol.L-1. Omental (n = 14) and subcutaneous
adipose (n = 28) biopsies approximately 2 cm by 3 cm by
0.5 cm in size were taken atraumatically without heat co-
agulation. The samples were stored in ice-cold physio-
logical salt solution before immediate transfer to the
laboratory and stored within one hour at −80°C. Blood for
serum glucose, insulin, triglycerides and cholesterol wasprocessed and analysed routinely at the Royal Derby Hos-
pital Pathology Laboratories.
Blood pressure was measured with subjects rested and
supine. Anthropometric measurements performed by
one trained person while the patient was standing. Waist
circumference was measured at the midpoint between
the iliac crest and costal margin, and hip circumference
was taken at the widest point around the hips. Neck cir-
cumference was measured at the level of the cricothyr-
oid cartilage and arm circumference was measured at
the midpoint between the shoulder and elbow. Skinfold
thickness was measured at 7 anatomical sites using
Harpenden calipers. The 7 sites were: tricep (posterior,
level with circumference), bicep (anterior, level with cir-
cumference), subscapular (parallel with inferior angle of
scapular), suprailiac (immediately superior to iliac crest),
abdominal (2 cm to the side of umbilicus), chest (as high
as possible between anterior axillary line and nipple) and
midaxillary (on midaxillary line, level of xiphoid process of
sternum) [27].
Isolation of mature adipocytes
The method used to obtain mature adipocytes was
adapted from Rodbell [28] as we have previously pub-
lished [14] for both human and rat adipose samples.
Adipose samples were thawed on ice, added to an equal
volume of type II collagenase in phosphate buffered sa-
line (PBS, 1 mg.ml-1, Sigma-Aldrich, UK) and digested at
37°C for 45 minutes. The samples were washed twice in
PBS using centrifugation (500 x g, 2 minutes) to separate
the mature adipocytes which formed a floating layer.
The isolated mature adipocytes were stored at −80°C
until homogenisation. Isolated mature adipocytes were
homogenised in TE buffer (50 mM Tris, 1 mM EDTA,
pH 7.4) using a hand-held glass homogeniser on ice.
The homogenates were centrifuged (18,000 x g, 10 mi-
nutes) and the supernatant removed and spun again
(20,000 x g, 30 minutes). The supernatant layer from this
step was then stored at −80°C as the cytosolic fraction.
The cellular pellet was homogenised in PBS (10 mM
phosphate, 2.7 mM potassium chloride, 137 mM sodium
chloride, pH 7.4), centrifuged (20,000 x g, 30 minutes),
resuspended and stored at −80°C as the total particulate
fraction.
Enzyme activity assays
Enzyme assays were carried out with minor modifica-
tions of the method of Boldrup et al. [29]. Samples of
the total cell particulate or cytosolic fraction (in dupli-
cate) were diluted in TE buffer (fatty acid free albumin
1 mg.ml-1, pH 7.4) and at 37°C for 10 min with the
FAAH inhibitor URB597 (1 μM, Sigma Chemical Com-
pany, UK) or vehicle. [3H]-AEA (American Radiolabelled
Chemicals, USA) was added to a final concentration of
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http://www.lipidworld.com/content/13/1/432 μM, and the samples were incubated at 37°C for
30 min. Activated charcoal (400 μl, 10% w/v in 0.5 M
HCl) was used to stop the reaction. After brief centrifu-
gation at approximately 13 000 x g, an aliquot of each
supernatant layer was taken for scintillation counting.
Tubes without homogenate were run in parallel to estab-
lish blank values. The total cell particulate or cytosolic
fraction was assayed for MGL activity using the same
method as above, substituting a MGL inhibitor, methy-
larachidonylfluorophosphonate (MAFP, 1 μM, Sigma
Chemical Company, UK), and 2-oleoyl-[3H]-glycerol
(2-OG, American Radiolabelled Chemicals, USA) to a
final concentration of 100 μM and incubated at 37°C
for 15 min. Concentrations of substrate (3H-AEA and
3H-2OG) were used at sub-saturating levels in order
to allow visualisation of any changes in either substrate
affinity or maximal hydrolysis rate.
Statistical analysis
GraphPad Prism software was used to analyse the data.
A D’Agostino & Pearson omnibus normality test was
carried out on all data and non-parametric analysis ap-
plied where appropriate. Where linear regression was
used, the Pearson or Spearman correlation coefficient is
reported. When three groups were compared, one-way
analysis of variance (ANOVA) was used with Bonferoni
multiple comparison (or Krustal Wallis for non-parametric
data). For comparison of two groups, either paired or un-
paired Student’s t test (or Wilcoxon signed rank test) was
used as appropriate.
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